These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8973673)

  • 1. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group.
    Fernandez del Moral P; Dijkman GA; Debruyne FM; Witjes WP; Kolvenbag GJ
    Urology; 1996 Dec; 48(6):894-900. PubMed ID: 8973673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.
    Sarosdy MF; Schellhammer PF; Soloway MS; Vogelzang NJ; Crawford ED; Presti J; Chodak GW; Mitchell P; Porter L
    BJU Int; 1999 May; 83(7):801-6. PubMed ID: 10368200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group.
    Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
    Eur Urol; 1995; 27(1):43-6. PubMed ID: 7744141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.
    Debruyne FM; Dijkman GA; Lee DC; Witjes WP; del Moral F; Karthaus HF; van der Mejden AP; Plasman JW; Pull HC; Kums JJ; Idema JG; Hoefakker JW; Heijbroek RP; Kil PJ; Khoe GS
    J Urol; 1996 Apr; 155(4):1352-4. PubMed ID: 8632572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial.
    Fontana D; Mari M; Martinelli A; Boccafoschi C; Magno C; Turriziani M; Maymone SS; Cunico SC; Zanollo A; Montagna G; Frongia M; Jacobellis U
    Urol Int; 2003; 70(4):316-20. PubMed ID: 12740498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
    Sharifi R; Knoll LD; Smith J; Kramolowsky E
    Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quality of life following endocrine therapy for advanced prostate cancer: a comparative study between LH-RH agonist 1-month depot and 3-month depot].
    Namiki S; Ishidoya S; Saito S; Mitsukawa S; Suzuki Y; Numata I; Arai Y
    Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):631-7. PubMed ID: 18697469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.
    Oefelein M
    J Urol; 2003 Jan; 169(1):251-5. PubMed ID: 12478147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
    Zinner NR; Bidair M; Centeno A; Tomera K
    Urology; 2004 Dec; 64(6):1177-81. PubMed ID: 15596193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.
    Chen N; Wang Z; Chen M; Ma Q; He Y; Wang Y; Li X; Qiu M; Shi L; Zhu S; Xie Q; Liu X; Shi B; Lin G; Yang W; Liao Y; Zhang H; Wang S; Li J; Wang S; Dong L; Chen H; Lu J; Cheng Y; Zhang X; Ma L; Zhou L; Wang H; Li S; Ye D
    Cancer Biol Med; 2024 Feb; 20(12):1047-59. PubMed ID: 38318809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.
    Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
    Eur Urol; 1994; 26 Suppl 1():1-2. PubMed ID: 7737253
    [No Abstract]   [Full Text] [Related]  

  • 19. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
    Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
    N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.